Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mimi I Hu

Showing results (81-90 of 92) with videos related to

Pageof 10
Sort By:
JCO Precision Oncology|July 9, 2025
Erratum: NTRK Fusion-Positive Thyroid Carcinoma: From Diagnosis to Targeted TherapyVicente R Marczyk, Sasan Fazeli, Ramona Dadu, et al.
JCO Precision Oncology|February 21, 2025
<i>NTRK</i> Fusion-Positive Thyroid Carcinoma: From Diagnosis to Targeted TherapyVicente R Marczyk, Sasan Fazeli, Ramona Dadu, et al.
Thyroid : Official Journal of the American Thyroid Association|November 27, 2023
Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW StudyVivek Subbiah, Mimi I Hu, Aaron S Mansfield, et al.
Cancer|November 2, 2018
Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignanciesMinny Bhatty, Shumei Kato, Sarina A Piha-Paul, et al.
Current Problems in Surgery|March 19, 2008
Recent advances in thyroid cancer. In briefElizabeth G Grubbs, Thereasa A Rich, Guojun Li, et al.
Current Problems in Surgery|March 19, 2008
Recent advances in thyroid cancerElizabeth G Grubbs, Thereasa A Rich, Guojun Li, et al.
Cancer Discovery|April 17, 2018
Precision Targeted Therapy with BLU-667 for <i>RET</i>-Driven CancersVivek Subbiah, Justin F Gainor, Rami Rahal, et al.
The Lancet. Diabetes & Endocrinology|June 12, 2021
Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 studyVivek Subbiah, Mimi I Hu, Lori J Wirth, et al.
The Journal of Clinical Endocrinology and Metabolism|June 26, 2025
Characterization of advanced RAS-driven follicular-derived thyroid cancers and review of future therapeutic avenuesSarah Hamidi, Anastasios Maniakas, Neal S Akhave, et al.
Head & Neck|May 22, 2020
Endocrine surgery in the Coronavirus disease 2019 pandemic: Surgical Triage GuidelinesYelda Jozaghi, Mark E Zafereo, Nancy D Perrier, et al.
Pageof 10

Showing results (81-90 of 92) with videos related to

Sort By:
Pageof 10
JCO Precision Oncology|July 9, 2025
Erratum: NTRK Fusion-Positive Thyroid Carcinoma: From Diagnosis to Targeted TherapyVicente R Marczyk, Sasan Fazeli, Ramona Dadu, et al.
JCO Precision Oncology|February 21, 2025
<i>NTRK</i> Fusion-Positive Thyroid Carcinoma: From Diagnosis to Targeted TherapyVicente R Marczyk, Sasan Fazeli, Ramona Dadu, et al.
Thyroid : Official Journal of the American Thyroid Association|November 27, 2023
Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW StudyVivek Subbiah, Mimi I Hu, Aaron S Mansfield, et al.
Cancer|November 2, 2018
Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignanciesMinny Bhatty, Shumei Kato, Sarina A Piha-Paul, et al.
Current Problems in Surgery|March 19, 2008
Recent advances in thyroid cancer. In briefElizabeth G Grubbs, Thereasa A Rich, Guojun Li, et al.
Current Problems in Surgery|March 19, 2008
Recent advances in thyroid cancerElizabeth G Grubbs, Thereasa A Rich, Guojun Li, et al.
Cancer Discovery|April 17, 2018
Precision Targeted Therapy with BLU-667 for <i>RET</i>-Driven CancersVivek Subbiah, Justin F Gainor, Rami Rahal, et al.
The Lancet. Diabetes & Endocrinology|June 12, 2021
Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 studyVivek Subbiah, Mimi I Hu, Lori J Wirth, et al.
The Journal of Clinical Endocrinology and Metabolism|June 26, 2025
Characterization of advanced RAS-driven follicular-derived thyroid cancers and review of future therapeutic avenuesSarah Hamidi, Anastasios Maniakas, Neal S Akhave, et al.
Head & Neck|May 22, 2020
Endocrine surgery in the Coronavirus disease 2019 pandemic: Surgical Triage GuidelinesYelda Jozaghi, Mark E Zafereo, Nancy D Perrier, et al.
Pageof 10